कृपया अन्य खोज का प्रयास करें
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Chris Buyse | 57 | 2017 | Independent Director |
Sven Francque | - | - | Member of Scientific Advisory Board |
Kenneth Cusi | - | - | Member of Scientific Advisory Board |
Manal Abdelmalek | - | - | Member of Scientific Advisory Board |
Glen Clack | - | - | Member of Scientific Advisory Board |
Jean-Louis Junien | 77 | 2016 | Chairman of Scientific Advisory Board |
Heinz Christoph Maeusli | 58 | 2019 | Independent Director |
Annick Schwebig | 70 | 2017 | Independent Director |
Xiaoqin Lu | 46 | 2018 | Independent Director |
Arun J. Sanyal | - | 2020 | Member of Scientific Advisory Board |
Andrew Shenker | 67 | 2019 | Member of Scientific Advisory Board |
Martine Zimmermann | 53 | 2021 | Independent Director |
Trever Bivona | - | 2022 | Member of the Scientific Advisory Board |
Elisabetta Bugianesi | - | 2022 | Member of the Scientific Advisory Board |
Gérard Zalcman | - | - | Scientific Advisory Board Member |
Frederic Cren | 58 | 2011 | Co-Founder, CEO & Chairman |
Pierre Broqua | 62 | 2011 | Co-Founder, Chief Scientific Officer, Deputy CEO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है